Stabilized mosaic hemagglutinin immunogens as novel universal influenza virus vaccines
Molecular Therapy · 2026-07 · 34 (7) · 4153-4168
DOI: 10.1016/j.ymthe.2026.03.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-07. Verfasst von Mitali Mishra und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Hemagglutinin Glycoproteins, Influenza Virus, Orthomyxoviridae Infections, Influenza, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Influenza virus undergoes frequent changes in its main surface glycoprotein, hemagglutinin (HA), evading pre-existing immunity acquired by a previous infection or vaccination. To overcome this challenge, we developed a novel vaccination strategy based on recombinant mosaic HAs (mHAs) that are stabilized without the use of an exogenous trimerization domain (foldon). These stabilized mHAs maintained high trimeric HA content and demonstrated enhanced stability at elevated temperatures and low pH. In mice, sequential immunization with stabilized mHAs redirected the antibody response toward conserved HA regions, resulting in broad protection against diverse influenza virus strains. Compared with foldon-containing constructs, stabilized mHAs improved epitope exposure while avoiding unwanted anti-foldon immune responses. We further compared the immune responses elicited by stabilized mHAs with those induced by conventional seasonal influenza vaccines. Notably, stabilized mHA vaccines conferred protection in the absence of hemagglutination inhibition antibodies, unlike seasonal influenza vaccines. This protection was mediated by a combination of serum neutralization and Fc effector functions predominantly targeting the HA stalk domain. Stabilized mHAs also provided broad cross-protection against homologous (pH1N1), heterologous (SwH1N2), and cross-subtype (H5N1) virus challenges in the mouse model. Overall, stabilized mHAs represent a promising alternative for the development of next-generation universal influenza virus vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029,…
- Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA.
- Drukier Institute for Children's Health, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10021, USA.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: peter.palese@ms…
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: irene.gonzalez@mssm.edu.
Förderung
- NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases Division of Intramural Research
Zitieren
APA
Mishra, M., Puente-Massaguer, E., Jones, A. T., Martínez-Guevara, J., Lai, T. Y., Abdeljawad, A., Ding, K., Zheng, N., Bournazos, S., Ravetch, J. V., Krammer, F., Wilson, P. C., Palese, P., & González-Domínguez, I. (2026). Stabilized mosaic hemagglutinin immunogens as novel universal influenza virus vaccines. Molecular Therapy, 34(7), 4153-4168. https://doi.org/10.1016/j.ymthe.2026.03.021
Vancouver
Mishra M, Puente-Massaguer E, Jones AT, Martínez-Guevara J, Lai TY, Abdeljawad A, et al. Stabilized mosaic hemagglutinin immunogens as novel universal influenza virus vaccines. Molecular Therapy. 2026;34(7):4153-4168. doi:10.1016/j.ymthe.2026.03.021
BibTeX
@article{Mishra2026,
author = {Mishra, Mitali and Puente-Massaguer, Eduard and Jones, Andrew T and Martínez-Guevara, Jose and Lai, Tsoi Ying and Abdeljawad, Adam and Ding, Kevin and Zheng, Naiying and Bournazos, Stylianos and Ravetch, Jeffrey V and Krammer, Florian and Wilson, Patrick C and Palese, Peter and González-Domínguez, Irene},
title = {Stabilized mosaic hemagglutinin immunogens as novel universal influenza virus vaccines},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {7},
pages = {4153--4168},
doi = {10.1016/j.ymthe.2026.03.021}
}
EUVIMED